Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148627 · ClinicalTrials.gov registry record · Phase 1
Safety Study of LY3041658 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02148627 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 54 participants.
The verdict
NCT02148627, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells. Study participation will last 4 months. Protocol amended in January, 2016 to include first generation Japanese participants.
Interventions
- DRUG Placebo
- DRUG LY3041658 (SC)
- DRUG LY3041658 (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2017-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02148627
The ClinicalTrials.gov registry entry for NCT02148627 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02148627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02148627 about?
NCT02148627 is a clinical study titled "Safety Study of LY3041658 in Healthy Participants". The main purpose of this study is to evaluate the safety of LY3041658 in healthy participants, including first generation Japanese. The study will also investigate how the drug is processed and affects key immune cells. Study participation will last 4 months. Protocol amended in January, 2016 to in...
What is the current status of trial NCT02148627?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2014-06-16. Estimated completion is 2017-02-11.
What interventions are being tested in trial NCT02148627?
The interventions under investigation include: Placebo (DRUG), LY3041658 (SC) (DRUG), LY3041658 (IV) (DRUG).
Who is sponsoring clinical trial NCT02148627?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.